NCT03989206

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,700 (estimated)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Detailed description

Long-term study to assess the safety and efficacy of nemolizumab in subjects with moderate-to-severe AD

Conditions

• Moderate-to-Severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Nemolizumab	Nemolizumab

Timeline

• Start date: 2019-12-30
• Primary completion: 2026-08-31
• Completion: 2026-08-31
• First posted: 2019-06-18
• Last updated: 2024-10-30

Locations

343 sites across 22 countries: United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study